Muscle Loss on GLP-1: What DEXA Substudies Show
A patient returns at week 52 of semaglutide therapy having lost 18% of baseline body weight. The scale result reads as an unambiguous success. The DEXA scan ordered alongside it tells a more…
Blog Topic
Safety & Side Effects
What the evidence reports on tolerability, adverse events, and contraindications across the incretin class — including muscle-preservation and dose-management considerations. Not medical advice; always consult a licensed clinician.
Gastroparesis & GLP-1 Agonists: Incidence, Risk, When to Stop
A 54-year-old patient with type 2 diabetes of 11 years' duration starts tirzepatide for weight management. By week 14, at the 10 mg maintenance dose, she reports bloating, early fullness after a…
Compounded Semaglutide vs FDA-Approved Brands: Stability and Sterility Considerations
A Formulation Problem That Reached the Emergency Department A patient presents with an injection-site abscess three weeks into a subcutaneous semaglutide protocol sourced from a state-licensed…
Long-Term Tirzepatide Maintenance Dosing: SURMOUNT-4 Withdrawal and Regain Findings
The scenario presents itself with increasing frequency in obesity medicine practice: a patient who has completed 36 weeks of tirzepatide (Mounjaro/Zepbound) titration, achieved 10 mg or 15 mg/week…
Tirzepatide and Sleep Apnea: What the SURMOUNT-OSA Trial Data Shows
A patient presents with severe obstructive sleep apnea — apnea-hypopnea index (AHI) of 64 events per hour — and a BMI of 39 kg/m². Two CPAP trials have failed: one due to claustrophobia, one due to…
GLP-1 Therapy and Lean Muscle Mass: Preserving Tissue During Rapid Weight Loss
GLP-1 therapy and lean muscle mass preservation represent one of the most clinically consequential body composition questions in pharmacological weight management. A patient on semaglutide 2.4 mg…
Semaglutide Dose Titration Schedules: Evidence-Based Protocols from Pivotal Trials
A patient with a BMI of 38 initiates semaglutide 0.25 mg/week (Wegovy) and advances on calendar schedule at week 4 to 0.5 mg. Nausea begins on day 2 of the new dose. At week 8, the prescriber…
GLP-1 Drug Holidays and Dose Tapering: Weight Regain Evidence and Clinical Considerations
The Patient Who Stopped Too Soon A 47-year-old woman, 214 lbs at peak, had worked down to 171 lbs over 14 months on semaglutide 2.4 mg weekly. She felt great. Her physician agreed she could take a…
Preventing GLP-1 Muscle Loss: Resistance Training and Protein Protocol During Weight Reduction
The Problem Nobody Warned Their Patients About A 54-year-old woman comes back for her 12-week semaglutide check-in. She's down 22 pounds. Her physician is thrilled. But when you pull up her DEXA…
GLP-1 Side Effects Guide
What the evidence and FDA prescribing information report on GLP-1 side effects, how GI symptoms are managed, and long-term safety data. Not medical advice.